Intelligent Bio Solutions (NASDAQ:INBS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Intelligent Bio Solutions (NASDAQ:INBS) from a hold rating to a sell rating in a research report report published on Sunday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Intelligent Bio Solutions Price Performance

Shares of NASDAQ:INBS opened at $1.03 on Friday. The firm has a market capitalization of $9.35 million, a PE ratio of -0.50 and a beta of 4.49. The business has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.49. Intelligent Bio Solutions has a 12 month low of $1.01 and a 12 month high of $2.75.

Intelligent Bio Solutions (NASDAQ:INBS) last announced its quarterly earnings results on Friday, August 15th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.25). The firm had revenue of $0.84 million for the quarter, compared to analyst estimates of $4.30 million. Intelligent Bio Solutions had a negative return on equity of 231.13% and a negative net margin of 346.22%. As a group, research analysts anticipate that Intelligent Bio Solutions will post -1.25 earnings per share for the current year.

Institutional Investors Weigh In On Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Altium Capital Management LLC bought a new stake in Intelligent Bio Solutions Inc. (NASDAQ:INBS) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 149,252 shares of the company’s stock, valued at approximately $215,000. Intelligent Bio Solutions makes up about 0.5% of Altium Capital Management LLC’s holdings, making the stock its 17th biggest holding. Altium Capital Management LLC owned about 2.19% of Intelligent Bio Solutions as of its most recent filing with the Securities & Exchange Commission. 32.97% of the stock is currently owned by institutional investors.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.